Last reviewed · How we verify
Bis-Choline Tetrathiomolybdate
Bis-Choline Tetrathiomolybdate is a Chelating agent Small molecule drug developed by Alexion Pharmaceuticals, Inc.. It is currently in Phase 2 development for Wilson's disease. Also known as: ALXN1840.
Bis-Choline Tetrathiomolybdate is a chelating agent that binds to copper, reducing its availability for incorporation into ceruloplasmin and subsequent deposition in the brain.
Bis-Choline Tetrathiomolybdate is a small molecule chelating agent that functions as a copper chelating agent. It is being studied in clinical trials for Wilson Disease and its effects on the metabolism of certain substances in healthy participants.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Bis-Choline Tetrathiomolybdate |
|---|---|
| Also known as | ALXN1840 |
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Drug class | Chelating agent |
| Target | Copper |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
This mechanism is thought to be beneficial in treating conditions such as Wilson's disease, where excessive copper accumulation in the brain leads to neurodegeneration. By reducing copper levels, Bis-Choline Tetrathiomolybdate may help slow or halt disease progression.
Approved indications
- Wilson's disease
Common side effects
- Hemolysis
Key clinical trials
- Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 (PHASE2)
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease (PHASE3)
- Bioavailability Study of 2 Oral Formulations of ALXN1840 (PHASE1)
- Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants (PHASE1)
- Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. (PHASE1)
- A Study of the Cardiac Effects of ALXN1840 in Healthy Adults (PHASE1)
- Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults (PHASE1)
- A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bis-Choline Tetrathiomolybdate CI brief — competitive landscape report
- Bis-Choline Tetrathiomolybdate updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Bis-Choline Tetrathiomolybdate
What is Bis-Choline Tetrathiomolybdate?
How does Bis-Choline Tetrathiomolybdate work?
What is Bis-Choline Tetrathiomolybdate used for?
Who makes Bis-Choline Tetrathiomolybdate?
Is Bis-Choline Tetrathiomolybdate also known as anything else?
What drug class is Bis-Choline Tetrathiomolybdate in?
What development phase is Bis-Choline Tetrathiomolybdate in?
What are the side effects of Bis-Choline Tetrathiomolybdate?
What does Bis-Choline Tetrathiomolybdate target?
Related
- Drug class: All Chelating agent drugs
- Target: All drugs targeting Copper
- Manufacturer: Alexion Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Wilson's disease
- Also known as: ALXN1840
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing